Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute of Human Genetics, |
RCV001706801 | SCV001934307 | likely pathogenic | Diastrophic dysplasia | 2020-11-09 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001882780 | SCV002182871 | pathogenic | Achondrogenesis, type IB; Atelosteogenesis type II; Multiple epiphyseal dysplasia type 4; Diastrophic dysplasia | 2023-04-28 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.His665Glnfs*11) in the SLC26A2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 75 amino acid(s) of the SLC26A2 protein. This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the SLC26A2 protein in which other variant(s) (p.Ala715Val) have been determined to be pathogenic (PMID: 8571951, 21077204, 21922596; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 1285445). This variant has not been reported in the literature in individuals affected with SLC26A2-related conditions. |
Baylor Genetics | RCV003474013 | SCV004201758 | likely pathogenic | Achondrogenesis, type IB | 2023-07-29 | criteria provided, single submitter | clinical testing |